Neuromyelitis Optica Spectrum Disorders clinical trials at UCSD
1 in progress, 0 open to eligible people
Sorry, not currently recruiting here
A Phase 2, open-label, multicenter study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of inebilizumab in eligible pediatric participants 2 to < 18 years of age with recently active neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for autoantibodies against aquaporin-4 (AQP4-immunoglobulin [Ig]G).
La Jolla, California and other locations
Our lead scientists for Neuromyelitis Optica Spectrum Disorders research studies include Jennifer Sharon Graves, MD, PhD.